Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of IRLAB Therapeutics AB was 7.40% per year. The lowest was -57.60% per year. And the median was -8.75% per year.
IRLAB Therapeutics AB (OSTO:IRLAB A) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
IRLAB Therapeutics AB 3-Year EPS without NRI Growth Rate Related Terms
OSTO:IRLAB A vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's 3-Year EPS without NRI Growth Rate falls into.
IRLAB Therapeutics AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.40% mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a 3-Year EPS without NRI Growth Rate of 7.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #709 out of 1155 companies in the Biotechnology industry, placing it in the top 61.4%.
Is IRLAB Therapeutics AB's 3-Year EPS without NRI Growth Rate too high?
IRLAB Therapeutics AB's current 3-Year EPS without NRI Growth Rate is 7.40%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.00. IRLAB Therapeutics AB's value of 7.40% is 53.8% below this industry median. Based on the distribution chart, IRLAB Therapeutics AB ranks #709 out of 1155 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #709 out of 1155 companies for 3-Year EPS without NRI Growth Rate. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.00. IRLAB Therapeutics AB's value of 7.40% is 53.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRLAB Therapeutics AB's current 3-Year EPS without NRI Growth Rate of 7.40% is 53.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current 3-Year EPS without NRI Growth Rate is 7.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.41, compared to a current price of kr1.73 — trading 76.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.40% and 53.8% below the Biotechnology industry median of 16.00. IRLAB Therapeutics AB's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current 3-Year EPS without NRI Growth Rate is 7.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.73 is trading 76.7% below its estimated GF Value™ of kr7.41.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
3-Year EPS without NRI Growth Rate: 7.40%
GF Value™: kr7.41 vs. price of kr1.73 (76.7% below fair value)
Industry Position: 53.8% below the Biotechnology median (#709 of 1155)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
38GF Score
Get the complete analysis for OSTO:IRLAB A
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
